ProNephro
AKI™ (NGAL)
The first biomarker assay for pediatric acute kidney injury risk assessment
Together we play a vital role in changing the course of acute kidney injury (AKI)
The Problem
AKI is a silent epidemic among hospitalized patients—affecting more than 1 in 4 childreni and 1 in 5 adults.ii Earlier AKI risk assessment can inform treatment decisions, minimize unnecessary intervention, and improve patient outcomes.
Revolutionizing Pediatric AKI Risk Assessment
BioPorto welcomes ProNephro AKI (NGAL) to its family of NGAL products in the race against kidney damage – the first FDA-cleared biomarker for pediatric acute kidney injury risk assessment. US commercial availability through Roche Diagnostics is expected in 2025.
*ProNephro AKI is FDA-cleared for use in the US. Commercial availability expected in 2025.
Join us in changing the kidney care paradigm
Stay up to date with the latest resources for kidney care, and news about BioPorto.